[9]Neer, R. M. et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in
postmenopausal women with osteoporosis. N. Engl. J.Med. 344, 1434–1441 (2001)
[10]Neer, R. M. et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in
postmenopausal women with osteoporosis. N. Engl. J.Med. 344, 1434–1441 (2001)
[11]Greenspan, S. L. et al. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med.146, 326–339 (2007)
[12]Andrews, E. B. et al. The US postmarketing surveillance study of adult osteosarcoma and
teriparatide: study design and findings from the first7 years. J. Bone Miner. Res. 27, 2429–2437 (2012)
[13]Horwitz, M. J. et al. A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover. J. Bone Miner. Res. 26,2287–2297 (2011)
[14]Miller, P. D. et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA
316, 722–733 (2016).
[15]Miller, P. D. et al. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial.Bone 120, 137–140 (2018).
[16]Eastell, R. et al. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE. Osteoporos. Int. 30,667–673 (2019).
[17]McClung, M. R. et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, doubleblind, phase 2, parallel group study. J. Bone Miner.Res. 33, 1397–1406 (2018)
[18]Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl.J. Med. 375, 1532–1543 (2016).
[19]Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis.N. Engl. J. Med. 377, 1417–1427 (2017).
[20] Lewiecki, E. M. et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study.J. Bone Miner. Res. 34, 419–428 (2018).
[21]Lewiecki, E. M. et al. A phase III randomized placebocontrolled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J. Clin.Endocrinol. Metab. 103, 3183–3193 (2018)
[22]Nioi, P. et al. Transcriptional profiling of laser capture microdissected subpopulations of the osteoblast lineage provides insight into the early response to sclerostin antibody in rats. J. Bone Miner. Res. 30,1457–1467 (2015).
[23]Chavassieux, P. et al. Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J. Bone Miner. Res. 34,1597–1608 (2019).
[24]Wang, B., Yang, Y., Abou-Samra, A. B. & Friedman, P. A.NHERF1 regulates parathyroid hormone receptor desensitization: interference with β-arrestin binding.Mol. Pharmacol. 75, 1189–1197 (2009).
[25]Bonafede, M. M. et al. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis. Osteoporos. Int. 26, 1203–1212(2015).
[26]Cosman, F. et al. Hip and spine strength effects of adding versus switching to teriparatide in
